Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy

Microvascular Research

Volumn 84, Issue 3, 2012, Pages 378-383

  Kerkeni, Mohsen ^a   Saïdi, Amel ^a   Bouzidi, Hassan ^b   Yahya, Slim Ben ^c   Hammami, Mohamed ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b CHU Tahar Sfar   (Tunisia)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; HEMOGLOBIN A1C; PENTOSIDINE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUP; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUNISIA;

AGED; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS; TUNISIA;

EID: 84868111331     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.07.006     Document Type: Article

References (52)

1. Aso Y., Takanashi K., Sekine K., Yoshida N., Takebayashi K., Yoshihara K., et al. Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy. J. Lab. Clin. Med. 2004, 144:92-99.
2. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
3. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. The AGE concept. Cardiovasc. Res. 1998, 37:586-600.
4. Challier M., Jacqueminet S., Benabdesselam O., Grimaldi A., Beaudeux J.L. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin. Chem. 2005, 51:1749-1750.
5. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
6. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and others carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991, 266:11654-11660.
7. Fong D.S., Aiello L., Gardner T.W. American Diabetes Association, Diabetes retinopathy. Diabetes Care 2003, 26:226-229.
8. Ghanem A.A., Elewa A., Arafa L.F. Pentosidine, and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy. Eur. J. Ophthalmol. 2011, 21:48-54.
9. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
10. -/- mice. J. Clin. Invest. 2008, 118:183-194.
11. Herman W.H., Aubert R.E., Engelgau M.M., Thompson T.J., et al. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet. Med. 1998, 15:1045-1051.
12. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
13. Hricik D.E., Schulak J.A., Sell D.R., Fogarty J.F., Monnier V.M. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int. 1993, 43:398-403.
14. Hudson B.I., Cater A.M., Harja E., Kalea A.Z., Arriero M., Yang H., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22:1572-1580.
15. Ibrahim A.S., El-Remessy A.B., Matragoon S., Zhang W., Patel Y., Khan S., Al-Gayyer M.M., El-Shishtway M.M., Liou G.I. Retinal microglial activation and inflammation induced by amadori-glycation albumin in a rat model of diabetes. Diabetes 2011, 60:1122-1133.
16. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 2:1414-1431.
17. Kislinger T., Fu C., Huber B., Taguchi A., Du Yan S., Hofmann M., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 1999, 274:31740-31749.
18. Kowluru R.A., Chan P.S. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res 2007, 2007:1-14.
19. McKay R., McCarty C.A., Taylor H.R. Diabetic retinopathy in Victoria, Australia: the Visual Impairment Projet. Br. J. Ophthalmol. 2000, 84:865-870.
20. Miyata T., Ueda Y., Shinzato T., Iida Y., Tanaka S., Kurokawa K., et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J. Am. Soc. Nephrol. 1996, 7:1198-1206.
21. Miyata T., Udea Y., Horie K., Nangaku M., Tanaka S., van Ypersele de Strihou C., Kurokawa K. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int. 1998, 53:416-422.
22. Monnier V.M., Sell D.R., Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann. N. Y. Acad. Sci. 2005, 1043:567-581.
23. Odetti P., Fogarty J., Sell D.R., Monnier V.M. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetes and uremic subject. Diabetes 1992, 41:153-159.
24. Pachydaki S.I., Tari S.R., Lee S.E., Ma W., Tseng J.J., Sosunov, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res 2006, 82:807-815.
25. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A. A soluble form of the receptor for advanced glycation end products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22:3716-3727.
26. Salman A.G., Mansour D.E., Swelem A.H., Al-Zawahary W.M., Radwan A.A. Pentosidine - a new biochemical marker in diabetic retinopathy. Ophthalmic Res. 2009, 42:96-98.
27. Sato E., Nagaoka T., Yokota H., Takahashi A., Yoshida A. Correlation between plasma pentosidine concentrations and retinal hemodynamics in patients with type 2 diabetes. Am. J. Ophthalmol. 2012, 153:903-909.
28. Schlueter C., Hauke S., Flohr A.M., Rogalla P., Bullerdiek M. Tissue-specific expression patterns of the RAGE receptor and its soluble forms: a result of regulated alternative splicing?. Biochim. Biophys. Acta 2003, 1630:1-6.
29. Stern D., Yan S.D., Yan S.F., Schmidt A.M. Receptor for advanced glycation end products: a mutiligand receptor magnifying cell stress in diverse pathologic setting. Adv. Drug Deliv. Rev. 2002, 54:1615-1625.
30. Stitt A.M., Bhaduri T., McMullen C.B., Gardiner T.A., Archer D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell. Biol. Res. Commun. 2000, 3:380-388.
31. Sugiyama S., Miyata T., Ueda Y., Tanaka H., Maeda K., Kawashima S., et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9:1681-1688.
32. Suliman M.E., Heimburger O., Barany P., Anderstam B., Pecoits-Filho R., Rodriguez Ayala E., et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J. Am. Soc. Nephrol. 2003, 14:1614-1622.
33. Sun J.K., Keenan H.A., Cavallerano J.D., Asztalos B.F., Strauch C., Monnier V.M., Doria A., Aiello L.P., King G.L. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration. Diabetes Care 2011, 34:968-974.
34. Takenaka K., Yamagishi S., Matsui T., Nakamura K., Imaizumi T. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr. Neurovasc. Res. 2006, 3:73-77.
35. Takeuchi M., Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimers's disease. J. Alzheimers Dis. 2009, 16:845-858.
36. Tan K.C., Shiu S.W., Chow W.S., Leng L., Bucala R., Betteridge D.J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006, 49:2756-2762.
37. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamomoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000, 275:25781-25790.
38. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000, 11:1656-1666.
39. Tarr J.M., Kaul K., Wolanska K., Kohner E.M., Chibber R. Retinopathy in diabetes. In diabetes: an old disease, a new insight 2011, Landes Bioscience. S. Ahmed (Ed.).
40. van Leiden H.A., Dekker J.M., Nijpels G., Heine R.J., Bouter L.M., et al. Blood pressure, lipids, and obesity are associated with retinopathy. The Hoorn Study. Diabetes Care 2003, 25:1320-1325.
41. Weiss M.F., Erhard P., Kader-Attia F.A., Wu Y.C., Deoreo P.B., Araki A., et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int. 2000, 57:2571-2585.
42. WHO (cited 2011). Available from:. http://www.who.int/diabetes/en/.
43. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther. Apher. Dial. 2009, 13:534-539.
44. Yamagishi S., Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12:362-368.
45. Yamagishi S., Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp. Clin. Res. 2004, 30:169-175.
46. Yamagishi S., Adachi H., Nakamura K., Matsui T., Jinnouchi Y., Takenaka K., Takeuchi M., Enomoto M., Furuki K., Hino A., Shigeto Y., Imaizumi T. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006, 55:1227-1231.
47. Yamagishi S., Matsui T., Nakamura K., Inoue H., Takeuchi M., Udea S., Okuda S., Imaizumi T. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2007, 40:10-15.
48. Yamagishi S., Matsui T., Nakamura K., Yoshida T., Takeuchi M., Inoue H., Yoshida Y., Imaizumi T. Pigment epithelium-derived factor (PEDF) suppresses expression of receptor for advanced glycation end products (RAGE) in the eye of diabetic rats. Ophthalmic Res. 2007, 39:92-97.
49. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Investig. Drugs 2008, 17:983-996.
50. Yamagishi S., Nakamura K., Matsui T., Noda Y., Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr. Pharm. Des. 2008, 14:487-495.
51. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 2003, 370:1097-1101.
52. Yoshida N., Okumura K., Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005, 53:345-350.